MUMBAI, Dec 27 (Reuters) - Indian drug maker Lupin Ltd. said on Wednesday it had ended a deal with Cornerstone BioPharma Inc. to co-develop an anti-infective drug for the U.S. market. Lupin said it would continue to develop the product and would seek a partner to market the product in the United States. The company did not give a reason for the ending the agreement, which it signed in May 2005. This comes a day after Lupin ended another deal with Chester Valley Pharmaceuticals to promote non-steroidal cream Atopiclair to U.S. paediatricians.
